A 68-year-old man with benign prostatic hyperplasia (BPH) is being evaluated for medical management. Which clinical feature best distinguishes BPH from prostate cancer in this patient?

Explanation

## Distinguishing BPH from Prostate Cancer ### Clinical Examination Findings **Key Point:** The texture and symmetry of prostate enlargement on digital rectal examination (DRE) is the single best clinical discriminator between BPH and prostate cancer. | Feature | BPH | Prostate Cancer | |---------|-----|------------------| | **Consistency** | Smooth, rubbery, elastic | Hard, nodular, irregular | | **Symmetry** | Symmetrical | Asymmetrical (often) | | **Borders** | Well-defined, mobile | Ill-defined, fixed | | **Induration** | Absent | Present (hard nodules) | | **Size** | Can be very large (>50g) | Variable, may be small | ### Why Each Finding Matters **High-Yield:** BPH causes **smooth, symmetrical, rubbery enlargement** due to hyperplasia of glandular and stromal tissue in the transition zone. This is the hallmark DRE finding. Prostate cancer typically presents with **hard, nodular, asymmetrical induration** because malignant tissue is denser and infiltrative, often arising in the peripheral zone. ### Limitations of Other Features **Clinical Pearl:** Both BPH and prostate cancer can present with: - Elevated PSA (PSA is produced by both benign and malignant prostatic epithelium) - Lower urinary tract symptoms (LUTS) such as nocturia, frequency, and urgency - Systemic findings like elevated alkaline phosphatase (only in advanced metastatic cancer) **Warning:** PSA elevation alone cannot distinguish BPH from cancer. PSA density, PSA velocity, and free PSA percentage are more specific, but DRE texture remains the most reliable clinical discriminator at the bedside.